MARKET

AVBP

AVBP

Arrivent Biopharma Inc
NASDAQ
30.95
-0.08
-0.26%
After Hours: 30.31 -0.64 -2.08% 19:55 09/04 EDT
OPEN
30.79
PREV CLOSE
31.03
HIGH
31.45
LOW
30.60
VOLUME
182.98K
TURNOVER
--
52 WEEK HIGH
35.83
52 WEEK LOW
17.00
MARKET CAP
1.53B
P/E (TTM)
-8.4300
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVBP last week (0831-0904)?
Weekly Report · 23m ago
Noteworthy Friday Option Activity: TYRA, CLYM, AVBP
NASDAQ · 2d ago
ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study
TipRanks · 3d ago
Weekly Report: what happened at AVBP last week (0824-0828)?
Weekly Report · 08/31 09:00
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case
Seeking Alpha · 08/27 08:00
Weekly Report: what happened at AVBP last week (0817-0821)?
Weekly Report · 08/24 09:00
Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 08/17 13:01
ArriVent BioPharma Price Target Raised to $47.00/Share From $44.00 by HC Wainwright & Co.
Dow Jones · 08/17 11:48
More
About AVBP
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4.

Webull offers Arrivent Biopharma Inc stock information, including NASDAQ: AVBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVBP stock methods without spending real money on the virtual paper trading platform.